Valneva

Initial results show excellent immune response after third. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop.

Pin By Kate Valneva On A N I M E Stone World Anime Baby Stone

About Valneva SE.

. Announcing topline results from its lot-to-lot trial for single-shot chikungunya vaccine candidate VLA1553 Valneva NASDAQVALN said that the Phase 3 study met its primary endpoint. About Valneva SE Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.

The Company has several vaccines in development including unique vaccines against Lyme disease COVID-19 and chikungunya. Valnevas portfolio also includes two. We would like to show you a description here but the site wont allow us.

Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop. Valneva NASDAQVALN announces positive homologous booster data from the Phase 12 study of its COVID-19 vaccine candidate VLA2001.

Pin Auf Corona